3 ms·

doesn't LSD affect those receptors (5ht2a)?

AnthonBerg 6y ago
It does! Thanks for asking, because: CORRECTION: I must correct my lay hands’ pollution of the information on paper. The ‘92 study on budesonide makes an indicative argument towards action on the 5-HT2 receptor subtype. I mistakenly overspecified the 5-HT2A sub-subtype. I hope it isn’t grievously incorrect. There are three 5-HT2 receptor subtypes, A, B, and C: https://en.wikipedia.org/wiki/5-HT2_receptor https://en.wikipedia.org/wiki/5-HT2_receptor – according to the individual Wikipedia entries, the 5-HT2A subtype is highly expressed on platelets, and the 5-HT2B is also expressed. No mention of platelets for the 5-HT2C subtype. It is indeed true that psychedelics are generally known as agonists of the 5-HT2A receptor. Seemingly they tend to be agonists of the B and C subtypes as well, as per Wikipedia. And interestingly enough, the substances known as psychedelics are also very significant and notable immunomodulators! As per this paper: Psychedelics and immunomodulation: novel approaches and therapeutic opportunities – A. Szabo, Frontiers of Immunology, 2015 – https://doi.org/10.3389/fimmu.2015.00358 https://doi.org/10.3389/fimmu.2015.00358 (I want to mention author A. Szabo’s credentials: The 2015 paper cites the researcher’s position at Department of Immunology, Faculty of Medicine, University of Debrecen, Hungary. Subsequent publications show a position at the NORMENT Center of Excellence (CoE), Institute of Clinical Medicine, University of Oslo and the Department of Medical Genetics, both at Oslo University Hospital, Norway. Source: https://loop.frontiersin.org/people/193869/overview https://loop.frontiersin.org/people/193869/overview – There is reason to assume that this is a serious and capable person.) There is mention of the Sigma-1 receptor as well in Szabo’s 2015 paper on immunomodulation. I want to take great care to not make spurious connections, but I did find this paper curious and interesting in this context: Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? - J. M. Vela, Frontiers of Immunology, November 2020 – https://www.frontiersin.org/articles/10.3389/fphar.2020.582310/full https://www.frontiersin.org/articles/10.3389/fphar.2020.5823... Via: https://twitter.com/EricLenze2/status/1364459057629773824 https://twitter.com/EricLenze2/status/1364459057629773824

It does! Thanks for asking, because: CORRECTION: I must correct my lay hands’ pollution of the information on paper. The ‘92 study on budesonide makes an indicative argument towards action on the 5-HT2 receptor subtype. I mistakenly overspecified the 5-HT2A sub-subtype. I hope it isn’t grievously incorrect. There are three 5-HT2 receptor subtypes, A, B, and C: https://en.wikipedia.org/wiki/5-HT2_receptor https://en.wikipedia.org/wiki/5-HT2_receptor – according to the individual Wikipedia entries, the 5-HT2A subtype is highly expressed on platelets, and the 5-HT2B is also expressed. No mention of platelets for the 5-HT2C subtype. It is indeed true that psychedelics are generally known as agonists of the 5-HT2A receptor. Seemingly they tend to be agonists of the B and C subtypes as well, as per Wikipedia. And interestingly enough, the substances known as psychedelics are also very significant and notable immunomodulators! As per this paper: Psychedelics and immunomodulation: novel approaches and therapeutic opportunities – A. Szabo, Frontiers of Immunology, 2015 – https://doi.org/10.3389/fimmu.2015.00358 https://doi.org/10.3389/fimmu.2015.00358 (I want to mention author A. Szabo’s credentials: The 2015 paper cites the researcher’s position at Department of Immunology, Faculty of Medicine, University of Debrecen, Hungary. Subsequent publications show a position at the NORMENT Center of Excellence (CoE), Institute of Clinical Medicine, University of Oslo and the Department of Medical Genetics, both at Oslo University Hospital, Norway. Source: https://loop.frontiersin.org/people/193869/overview https://loop.frontiersin.org/people/193869/overview – There is reason to assume that this is a serious and capable person.) There is mention of the Sigma-1 receptor as well in Szabo’s 2015 paper on immunomodulation. I want to take great care to not make spurious connections, but I did find this paper curious and interesting in this context: Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? - J. M. Vela, Frontiers of Immunology, November 2020 – https://www.frontiersin.org/articles/10.3389/fphar.2020.582310/full https://www.frontiersin.org/articles/10.3389/fphar.2020.5823... Via: https://twitter.com/EricLenze2/status/1364459057629773824 https://twitter.com/EricLenze2/status/1364459057629773824